Cannabidiol—the non-psychoactive cannabis compound better known as CBD—is a potent blocker of SARS-CoV-2 replication in human cells, new research shows. Not only that, but a survey of real-world patients taking prescribed CBD found a “significant” negative relationship between CBD consumption and COVID-19 infection.
As detailed in a paper published Thursday in the peer-reviewed journal Science Advances by a team of 33 researchers at the University of Chicago and University of Louisville, a survey of 1,212 U.S. patients taking prescribed CBD found that people taking 100 milligrams-per-milliliter oral doses of CBD returned positive COVID-19 tests at much lower rates than control groups with similar medical backgrounds who did not take CBD.
According to the study, all of the patients were people who had seizure-related conditions, which CBD is often prescribed to treat. Of this group, 6.2 percent returned positive COVID-19 tests or a diagnosis, compared to 8.9 percent in the control group. Among a smaller subset of patients who were likely taking CBD on the dates of their first COVID-19 test, the effect was even more pronounced: Only 4.9 percent of people taking CBD became infected with COVID-19, compared to 9 percent in the control group.
“Our results suggest that CBD and its metabolite 7-OH-CBD can block SARS-CoV-2 infection at early and even later stages of infection,” the study states.
Always good news when science-based testing, well-measured data, indicates additional benefits beyond the original study’s direction. A positive, albeit accidental, find.